Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Free Radic Res ; 29(5): 377-87, 1998 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9925030

RESUMEN

To define the molecular mechanism(s) of carvedilol inhibition of lipid peroxidation we have utilized model systems that allow us to study the different reactions involved in this complex process. Carvedilol inhibits the peroxidation of sonicated phosphatidylcholine liposomes triggered by FeCl2 addition whereas atenolol, pindolol and labetalol are ineffective. The inhibition proved not to be ascribable (a) to an effect on Fe2+ autoxidation and thus on the generation of oxygen derived radical initiators; (b) to the scavenging of the inorganic initiators O2*- and *OH; (c) to an effect on the reductive cleavage of organic hydroperoxides by FeCl2; (d) to the scavenging of organic initiators. The observations that (a) carvedilol effectiveness is inversely proportional to the concentration of FeCl2 and lipid hydroperoxides in the assay; (b) the drug prevents the onset of lipid peroxidation stimulated by FeCl3 addition and; (c) it can form a complex with Fe3+, suggest a molecular mechanism for carvedilol action. It may inhibit lipid peroxidation by binding the Fe3+ generated during the oxidation of Fe2+ by lipid hydroperoxides in the substrate. The lag time that carvedilol introduces in the peroxidative process would correspond to the time taken for carvedilol to be titrated by Fe3+; when the drug is consumed the Fe3+ accumulates to reach the critical parameter that stimulates peroxidation. According to this molecular mechanism the antioxidant potency of carvedilol can be ascribed to its ability to bind a species, Fe3+, that is a catalyst of the process and to its lipophilic nature that concentrates it in the membranes where Fe3+ is generated by a site specific mechanism.


Asunto(s)
Antioxidantes , Carbazoles/farmacología , Peroxidación de Lípido/efectos de los fármacos , Propanolaminas/farmacología , Carvedilol , Cloruros , Compuestos Férricos/metabolismo , Compuestos Férricos/farmacología , Compuestos Ferrosos/análisis , Compuestos Ferrosos/farmacología , Depuradores de Radicales Libres , Radical Hidroxilo/metabolismo , Cinética , Peróxidos Lipídicos/análisis , Liposomas/metabolismo , Oxidación-Reducción , Consumo de Oxígeno , Fosfatidilcolinas/metabolismo , Sonicación , Superóxidos/metabolismo
2.
Free Radic Res ; 33(1): 105-14, 2000 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10826926

RESUMEN

To define the molecular mechanism(s) of resveratrol inhibition of lipid peroxidation we have utilized model systems that allow us to study the different reactions involved in this complex process. Resveratrol proved (a) to inhibit more efficiently than either Trolox or ascorbate the Fe2+ catalyzed lipid hydroperoxide-dependent peroxidation of sonicated phosphatidylcholine liposomes; (b) to be less effective than Trolox in inhibiting lipid peroxidation initiated by the water soluble AAPH peroxyl radicals; (c) when exogenously added to liposomes, to be more potent than alpha-tocopherol and Trolox, in the inhibition of peroxidation initiated by the lipid soluble AMVN peroxyl radicals; (d) when incorporated within liposomes, to be a less potent chain-breaking antioxidant than alpha-tocopherol; (e) to be a weaker antiradical than alpha-tocopherol in the reduction of the stable radical DPPH*. Resveratrol reduced Fe3+ but its reduction rate was much slower than that observed in the presence of either ascorbate or Trolox. However, at the concentration inhibiting iron catalyzed lipid peroxidation, resveratrol did not significantly reduce Fe3+, contrary to ascorbate. In their complex, our data indicate that resveratrol inhibits lipid peroxidation mainly by scavenging lipid peroxyl radicals within the membrane, like alpha-tocopherol. Although it is less effective, its capacity of spontaneously entering the lipid environment confers on it great antioxidant potential.


Asunto(s)
Antioxidantes/farmacología , Peroxidación de Lípido/efectos de los fármacos , Picratos , Estilbenos/farmacología , Ácido Ascórbico/farmacología , Bepridil/análogos & derivados , Bepridil/metabolismo , Compuestos de Bifenilo , Cromanos/farmacología , Depuradores de Radicales Libres/farmacología , Radicales Libres/metabolismo , Técnicas In Vitro , Hierro/metabolismo , Liposomas , Resveratrol , Vitamina E/farmacología
3.
Biochem Biophys Res Commun ; 213(3): 820-6, 1995 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-7654243

RESUMEN

It has been suggested that hypotaurine might inhibit lipid peroxidation in vivo by scavenging the initiator OH. The results presented demonstrate that hypotaurine affects other reactions relevant to the initiation, propagation and termination phases of lipid peroxidation. Hypotaurine a) decreases Fe2+ autoxidation, either spontaneous or catalyzed by Fe3+, that may generate perferryl iron; b) decreases Fe2+ oxidation, by cumene hydroperoxide, that forms the alkoxy radical; c) inhibits the lipid hydroperoxide dependent lipid peroxidation, favoring the onset of the termination phase. Hypotaurine does not affect the autoxidation of Fe2+ bound to phosphatidic acid containing liposomes. Taurine is ineffective in all the experimental systems tested.


Asunto(s)
Peroxidación de Lípido/efectos de los fármacos , Taurina/análogos & derivados , Taurina/farmacología , Dimiristoilfosfatidilcolina , Compuestos Férricos/metabolismo , Compuestos Ferrosos/metabolismo , Liposomas , Oxidación-Reducción , Ácidos Fosfatidicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA